Skip to main content

Table 2 Therapeutic responses to methotrexate

From: Randomized controlled trial design in rheumatoid arthritis: the past decade

    ACR ≥ 20 responses at
Study/Trial Mean disease duration Median MTX dose (mg/week) 12 months 24 months
Haagsma, et al. [74] 3 months 10 71% NR
Möttönen, et al. [57] 8 months 10 78% 84%
ERA [12, 75] 11 months 18a 65% 59%
MN 302 [15] 3.8 years 10 65%b 72%
US 301 [5] 6.5 years 15a 46%b 67%
ASPIRE [10] 7 months 19a 54%b NR
TEMPO [13] 6.6 years 17a 75% 71%
PREMIER [11] 8 to 9 months 16a 63%b 56%
  1. Therapeutic responses to methotrexate (MTX) are not consistent across trials and cannot be explained solely by differences in duration of disease or median MTX dose. aWith regular folate supplementation. bDesignated 12 month outcomes were analyzed with an intention to treat (ITT) analysis with non-responder imputation (NRI) for study non-completers. All other 12 month outcomes were analyzed by ITT with last observation carried forward (LOCF) for non-completers. ACR, American College of Rheumatology; ASPIRE, Active Controlled Study of Patients Receiving Infliximab for Treatment of Rheumatoid Arthritis of Early Onset; ERA, Early Rheumatoid Arthritis; NR, not recorded; TEMPO, Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes.